Pharma Supply Chain Risk in 2026: What GMP Leaders Must Control

Post-COVID Reality: How Work Expectations Have Changed for Pharma Quality Professionals

The QP’s Toughest Decisions: Navigating the Regulatory “Grey Zone”

Why QP Training Builds Better Pharma Leaders—Not Just Qualified Persons

FDA Quality Management Maturity Explained: Why It Impacts Inspections

ICH Q9 and QP Liability: When Rejecting a Batch Increases Patient Risk

How Pharma Quality Professionals Can Future-Proof Their Careers

Life as a Qualified Person: Why the QP Role Is Never a Desk Job

When Quality Culture Fails: The Leadership Gaps Regulators Notice

Can QPs Use AI Safely? The Regulatory Risk You Need to Understand

Why Poor Leadership Is Showing Up in GMP Inspection Reports

Hidden GMP Delays: How Value Stream Mapping Prevents Inspection Findings

FDA’s New Quality Framework: What Pharma Leaders Must Change Now

Is Pharma Hiring Is Changing? What It Means for Quality & Compliance Careers

Is the Life Sciences Job Market Really the “New Normal”?

Are Pharma Companies Expecting Too Much AI Experience from Candidates?

The Origins of the Qualified Person (QP): A 50-Year Regulatory Legacy

Why Most UK Qualified Persons Aren’t Pharmacists

What Internal Reviews Often Miss

AI & Decentralized Manufacturing: How Regulators Are Reshaping Pharma

Drug Shortages Explained: Why They’re Rising—and What Pharma Can Do Now

QA & QP Hiring: AI Skills, Auditing Demand, and Career Survival

Why Senior Leadership Is Driving GMP Failures — and How to Stop It

How the EU Is Tackling Medicine Shortages: NSF Pharma Biotech Conference 2024

Generative AI in Life Sciences: How NSF Is Reimagining Trials, Devices & GXP

AI in the Micro Lab: How AstraZeneca Uses Automated Colony Counting in Aseptic Manufacturing

AI in Pharma: Michael Hidock Explains the Real Future of Automation, R&D, and FDA Expectations

AI, Drug Shortages & Global Regulation: Dr. Peter Gough’s 2024 Update

Why Medicine Shortages Are Rising: Paul Fleming on Generics, Brexit and Supply Resilience

The Future of Quality Management Systems: Are You Ready for What’s Coming?

Innovation with Purpose: Alan Moon on Annex 1, Risk, and Patient Protection

NSF Pharma Biotech Conference 2023 - Paul O'Connor, Almac

NSF Pharma Biotech Conference 2023 - Rachel Carmichael

Quality Culture, QMM & the Future of Pharma

NSF Pharma Biotech Conference 2025 -Newaj Khan

AI in Pharma: Enabler or Risk? Inside the NSF Panel on Trust, Quality & Compliance

NSF Pharma Biotech Conference 2025 - Niamh Bissett

Contamination Control, Quality Culture, and Workforce: 2025 NSF Pharma Biotech Conference Q&A

NSF Pharma Biotech Conference 2025 - Adam Walker and Marc Sutton

Compliance vs. Quality Culture: What the Opinium Report Reveals About Pharma in 2026

NSF Pharma Biotech Conference 2025. Dr. Peter Gough - AI & Decentralised Manufacturing

Europe’s Pharma Quality Benchmark 2025: The Insights Every Leader Must Know

How Strong Leadership Transforms Regulatory and Operational Challenges

What’s Changing at the FDA? Dr. Julia Marré Explains the New U.S. Regulatory Landscape

AI in Pharma: Practical Use Cases Transforming Research, Regulatory and Medical Affairs

NSF/ANSI 305: The State of Conscious Beauty

NSF/ANSI 305 Personal Care Products Containing Organic Ingredients: A Technical Review 091825

NSF Webinar on the Life Science Sector in Ireland: Promo

Navigating Strengthening Organic Enforcement (SOE) Compliance Part 1

Navigating Strengthening Organic Enforcement (SOE) Compliance Part 2

NSF QP Training – Expert Tutoring and Personalized Mentoring

Redefining QP Training

Pathways to Becoming A Qualified Person (QP)

The Requirements to Become a QP (Qualified Person)

NSF Celebrates 35 Years of Qualified Person (QP) Training

The Future of QP Training: Skills, Talent, and Career Pathways

Compliance Unlocked Episode 2: Building A Quality Culture, and more

Inside the QP Role: Risk, Pressure, and Leading Quality in Pharma

How to Survive—and Succeed—During Pharma Regulatory Inspections

FDA Inspection Readiness Explained: What Regulators Really Want to See